Table 12.

Consensus meeting statements regarding ICIs in urothelial bladder cancer

Proposed statements	Level of agreement			N	Consensus achieved
	Disagree (%)	Equivocal (%)	Agree (%)
1. Pseudo-progression has not been demonstrated in urothelial cancer	0	11	89	28	Yes
2. In contrast to the first-line setting, the PD-L1 biomarker is not useful for selecting patients for immunotherapy in platinum-refractory metastatic urothelial cancer	4	15	81	28	Yes
3. Carboplatin-based chemotherapy remains a viable first-line treatment option in cisplatin-ineligible, PD-L1-positive patients with metastatic urothelial carcinoma until data from randomised phase III trials of ICIs are available	3	10	87	29	Yes
4. Cisplatin-ineligible, immunotherapy-refractory patients with metastatic urothelial carcinoma should be considered for chemotherapy instead of sequencing of immunotherapy	7	12	81	27	Yes

Statements highlighted in green achieved consensus.

ICI, immune checkpoint inhibitor; N, number of voters; PD-L1, programmed death-ligand 1.